Form 4: ResMed CEO Farrell Exercises Options, Sells Shares

ResMed Chairman and CEO Michael J. Farrell exercised stock options and subsequently sold an equal number of shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc., engaged in transactions on February 9, 2026.
• He exercised options to acquire 4,991 shares of ResMed Common Stock at an exercise price of $146.34 per share.
• Concurrently, he sold 4,991 shares of ResMed Common Stock at a weighted average price of $273.7801 per share, with individual trades ranging from $270.25 to $276.35.
• These transactions were conducted under a Rule 10b5-1 plan adopted on October 31, 2024.
• Following these transactions, Mr. Farrell directly owns 466,223 shares of common stock and indirectly owns 2,090 shares through the Lisette and Michael Farrell Family Trust.
• He also beneficially owns 44,921 unexercised ResMed Common Stock Options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation management under a transparent 10b5-1 plan, which reduces concerns about opportunistic selling.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating planned and transparent insider trading activity.
• The exercise of options and subsequent sale demonstrates the executive monetizing vested equity while maintaining significant beneficial ownership.
• The sale price of $273.7801 is significantly higher than the exercise price of $146.34, indicating a profitable transaction for the executive.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be perceived by some as a reduction in direct equity exposure.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives to manage their equity compensation and personal finances in a compliant manner. This transaction does not inherently reflect a change in company strategy or industry outlook.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be viewed as a slight reduction in direct insider alignment, though the pre-planned nature mitigates negative interpretations. The executive retains significant direct and indirect ownership.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Recommendation

The transaction is a routine, pre-planned sale by an executive under a 10b5-1 plan, which typically does not signal a change in company fundamentals or outlook. While a sale reduces direct insider ownership, the executive retains a substantial stake. Therefore, it does not warrant a change in investment thesis based solely on this filing.

Keywords

ResMed, RMD, Michael J. Farrell, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO, Chairman, Equity Compensation